A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Preserved Ejection Fraction
Latest Information Update: 30 Jun 2025
At a glance
- Drugs Tovinontrine (Primary)
- Indications Chronic heart failure
- Focus Proof of concept; Therapeutic Use
- Acronyms Cycle-2-PEF
- Sponsors Cardurion Pharmaceuticals
Most Recent Events
- 24 Jun 2025 Status changed from recruiting to active, no longer recruiting.
- 16 Jul 2024 According to a Cardurion Pharmaceuticals media release, company announced it has raised a $260 million Series B financing led by Ascenta Capital and proceeds from the financing will be used to support later-stage clinical trials with the company's two lead drug candidates CRD-750 and CRD-4730.
- 08 Mar 2024 Status changed from not yet recruiting to recruiting.